What the FDA labels say about taking them together
Rolapitant and rosuvastatin
Rolapitant's FDA label of August 19, 2020 names rosuvastatin in its drug interactions section; the rosuvastatin labels PlainMeds reads (2) do not name rolapitant. The rolapitant label: “Increased plasma concentrations of BCRP substrates may result in potential adverse reactions.”
Check it at the source: the rolapitant FDA label on DailyMed (effective August 19, 2020, TerSera Therapeutics LLC); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).
What does the rolapitant label say about rosuvastatin?
Rolapitant label, drug interactionsClinical Impact: Increased plasma concentrations of BCRP substrates (…) may result in potential adverse reactions. Intervention: Monitor for adverse reactions related to the concomitant drug if use of VARUBI cannot be avoided. Use the lowest effective dose of rosuvastatin (see prescribing information for additional information on recommended dosing).
Source: FDA drug label (Varubi), TerSera Therapeutics LLC, effective August 19, 2020 (SPL set a52896cd-4a98-49b8-82db-bf1985a64d97), via openFDA; the full label on DailyMed
What does the rosuvastatin label say about rolapitant?
Rosuvastatin's label (effective September 4, 2026) and its 1 other brand-application label do not name rolapitant in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rolapitant | Rosuvastatin | |
|---|---|---|
| Labeled for | n/a | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.0692 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once